CoChat

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

Abstract Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8 + cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201911571

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure EV1 MB enhances cytotoxicity of activated CTL against PD‐L1 expressing target cells ASchematic diagram for compounds screening on Jurkat and Raji stable lines.BScatterplot of relative luciferase activity of JP‐luc stimulated with SEE‐loaded Raji‐L1 in the presence of 1 μM chemicals. Y axis denotes the ratio of luciferase of chemical treated well against that of DMSO treated well. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.CFACS analysis of the cytotoxic efficiency of OT‐I CTLs against EG7‐L1 in the presence of MB. aPD1 antibody served as positive control. Splenocytes from OT‐I mice in culture were stimulated with 10 nM of SINFEEKL peptide for 3 days to generate mature CTLs. CTLs were incubated with CFSE‐labeled EG7‐L1 cells in the presence of MB at indicated concentrations. Cytotoxicity was determined by flow cytometry. Data are representative of three independent experiments (effector‐to‐target ratio = 10:1, 5:1, 2:1, unpaired t‐test, killing time: 5 h). EG7‐L1: EG7 overexpressing PD‐L1.DStatistical results of (Fig EV1C).EMB enhanced cytotoxicity of OT‐I CTLs against IFNγ‐treated B16‐F10‐OVA. Cytotoxicity was determined by the relative area unoccupied by crystal violet stained cells examined under microphotograph.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure EV1 MB enhances cytotoxicity of activated CTL against PD‐L1 expressing target cells ASchematic diagram for compounds screening on Jurkat and Raji stable lines.BScatterplot of relative luciferase activity of JP‐luc stimulated with SEE‐loaded Raji‐L1 in the presence of 1 μM chemicals. Y axis denotes the ratio of luciferase of chemical treated well against that of DMSO treated well. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.CFACS analysis of the cytotoxic efficiency of OT‐I CTLs against EG7‐L1 in the presence of MB. aPD1 antibody served as positive control. Splenocytes from OT‐I mice in culture were stimulated with 10 nM of SINFEEKL peptide for 3 days to generate mature CTLs. CTLs were incubated with CFSE‐labeled EG7‐L1 cells in the presence of MB at indicated concentrations. Cytotoxicity was determined by flow cytometry. Data are representative of three independent experiments (effector‐to‐target ratio = 10:1, 5:1, 2:1, unpaired t‐test, killing time: 5 h). EG7‐L1: EG7 overexpressing PD‐L1.DStatistical results of (Fig EV1C).EMB enhanced cytotoxicity of OT‐I CTLs against IFNγ‐treated B16‐F10‐OVA. Cytotoxicity was determined by the relative area unoccupied by crystal violet stained cells examined under microphotograph.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 1 MB enhances cytotoxicity of activated CTL against PD‐L1 expressing target cells AStructural formula of 3,7‐bis(dimethylamino)‐5‐phenothiazinium chloride (MB).BImpact of MB on cytotoxicity of OT‐1 CTLs against EG7 or EG7‐L1. Splenocytes from OT‐1 mice in culture were stimulated with 10 nM of OVA257–264 (SIINFEKL) for 3 days to generate mature CTLs. CTLs were incubated with CFSE‐labeled EG7‐L1 cells in the presence of MB at indicated concentrations. Cytotoxicity was determined by flow cytometry analysis. Data are representative of three independent experiments (effector‐to‐target ratio = 5:1, unpaired t‐test). EG7‐L1: EG7 overexpressing PD‐L1.CStatistical results of (B).DELISA measured of LDH release to assess the cytotoxicity of OT‐I CTLs on EG7‐L1 in the presence of MB. Anti‐PD1 antibody (aPD‐1) served as positive control.EImpact of MB on cytotoxicity of PD‐1−/− (PD‐1KO) OT‐1 CTLs against EG7 or PD‐L1 expressing EG7 stable cell line. Data are representative of three independent experiments (unpaired t‐test).FStatistical results of (E).GCytotoxicity of OT‐I CTLs against B16‐F10‐OVA cells (designated B16‐OVA) in the presence of 1 μM of MB or DMSO. Cytotoxicity was determined by the relative area unoccupied by cells examined under microscope (scale bar = 50 μm). Data are representative of three independent experiments and were analyzed by unpaired t‐test.HStatistical results of (G).Data information: Data are representative of three independent experiments. Unpaired t‐test; error bars denote SEM. **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 1 MB enhances cytotoxicity of activated CTL against PD‐L1 expressing target cells AStructural formula of 3,7‐bis(dimethylamino)‐5‐phenothiazinium chloride (MB).BImpact of MB on cytotoxicity of OT‐1 CTLs against EG7 or EG7‐L1. Splenocytes from OT‐1 mice in culture were stimulated with 10 nM of OVA257–264 (SIINFEKL) for 3 days to generate mature CTLs. CTLs were incubated with CFSE‐labeled EG7‐L1 cells in the presence of MB at indicated concentrations. Cytotoxicity was determined by flow cytometry analysis. Data are representative of three independent experiments (effector‐to‐target ratio = 5:1, unpaired t‐test). EG7‐L1: EG7 overexpressing PD‐L1.CStatistical results of (B).DELISA measured of LDH release to assess the cytotoxicity of OT‐I CTLs on EG7‐L1 in the presence of MB. Anti‐PD1 antibody (aPD‐1) served as positive control.EImpact of MB on cytotoxicity of PD‐1−/− (PD‐1KO) OT‐1 CTLs against EG7 or PD‐L1 expressing EG7 stable cell line. Data are representative of three independent experiments (unpaired t‐test).FStatistical results of (E).GCytotoxicity of OT‐I CTLs against B16‐F10‐OVA cells (designated B16‐OVA) in the presence of 1 μM of MB or DMSO. Cytotoxicity was determined by the relative area unoccupied by cells examined under microscope (scale bar = 50 μm). Data are representative of three independent experiments and were analyzed by unpaired t‐test.HStatistical results of (G).Data information: Data are representative of three independent experiments. Unpaired t‐test; error bars denote SEM. **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure EV2 MB enhanced activation and effector function of CTL AEffect of PD‐1 antibody on the proliferation of OT‐I CTLs. Splenocytes from OT‐I mice were labeled with CFSE and seeded in a 96‐well plate. Media were supplemented with 10 nM of SINFEEKL peptide, 10 ng/ml of human IL‐2 and 10 μg/ml of mouse PD‐L1 protein in the presence of 10 μg/ml of PD‐1 antibody. Cell proliferation was measured by FACS.BBar graph of (Fig EV2A).CMB enhancing production of cytokine and cytolytic granule by OT‐1 CTLs. CTLs were co‐incubated with CFSE‐labeled EG7‐L1 cells in the presence of protein transport inhibitor (PTI) and MB at indicated concentrations. Expression of cytokine and cytolytic granule was determined by flow cytometry. aPD‐1 antibody served as positive control. EG7‐L1: EG7 overexpressing PD‐L1.DBar graph of IFNγ production of OT‐1 CTLs in (Fig EV2C).EBar graph of GZMB production of OT‐1 CTLs in (Fig EV2C).Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure EV2 MB enhanced activation and effector function of CTL AEffect of PD‐1 antibody on the proliferation of OT‐I CTLs. Splenocytes from OT‐I mice were labeled with CFSE and seeded in a 96‐well plate. Media were supplemented with 10 nM of SINFEEKL peptide, 10 ng/ml of human IL‐2 and 10 μg/ml of mouse PD‐L1 protein in the presence of 10 μg/ml of PD‐1 antibody. Cell proliferation was measured by FACS.BBar graph of (Fig EV2A).CMB enhancing production of cytokine and cytolytic granule by OT‐1 CTLs. CTLs were co‐incubated with CFSE‐labeled EG7‐L1 cells in the presence of protein transport inhibitor (PTI) and MB at indicated concentrations. Expression of cytokine and cytolytic granule was determined by flow cytometry. aPD‐1 antibody served as positive control. EG7‐L1: EG7 overexpressing PD‐L1.DBar graph of IFNγ production of OT‐1 CTLs in (Fig EV2C).EBar graph of GZMB production of OT‐1 CTLs in (Fig EV2C).Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 2 MB enhanced activation and effector function of CTL AEffect of MB on the proliferation of WT CTLs and PD‐1KO CTLs. Splenic cells were stained with 5 μM of CFSE and seeded into aCD3/aCD28‐coated 96‐well plates. 10 μg/ml of PD‐L1 was administered in media. Cell proliferation was checked by monitoring dilution of CFSE 48 h after CD3/CD28 stimulation by gating on CD8‐positive population through FACS analysis. WT: splenic cell from wild‐type C57BL/J mice. PD‐1KO: splenic cell from PD‐1 knockout mice.BStatistical results of (A).CFACS analysis of the effect of MB on the activation of OT‐I CTLs. OT‐I CTLs were stimulated with precoated aCD3/aCD28 and 10 μg/ml of mouse PD‐L1 protein in the presence of 100 nM MB or 10 μg/ml aPD1 (served as positive control). After 24 h, surface expression of CD25 and CD69 on OT‐1 CTLs was determined through FACS analysis.DStatistical results of (C).EEffect of MB on the activation status of Jurkat T cells. Luciferase activity is suppressed in JP‐luc by co‐culture with Raji‐L1 preloaded with 1 μg/ml superantigen (SEE). Treatment with MB enhanced luciferase expression (SEE‐loaded Raji (PD‐L1 negative) served as positive control). IC50 is calculated to be 117 nM. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.FImpact of MB on luciferase activity of various engineered Jurkat T cells. J‐luc: Jurkat cell harboring NFAT‐luciferase transgene; J‐luc‐sgPD‐1: J‐luc cells treated with lentivirus expressing sgPD‐1/CAS9 simultaneously.GqRT–PCR analysis of IL‐2 mRNA level in JP‐luc cells stimulated with precoated aCD3/aCD28 (10 μg/ml) in the presence of 10 μg/ml of PD‐L1 and MB at indicated concentrations.HMB enhancing IL‐2 expression by JP‐luc stimulated with Raji‐L1 for 24 h quantified through ELISA analysis (aPD1 served as positive control).IMB enhancing production of cytokine and cytolytic granule by OT‐I CTLs. CTLs were incubated with EG7‐L1 cells in the presence of protein transport inhibitor (PTI) and MB at indicated concentrations. Expression of cytokine and cytolytic granule was determined by flow cytometry. aPD1 served as positive control. EG7‐L1: EG7 overexpressing PD‐L1.JStatistical results of (I).Data information: Data are representative of three independent experiments. Unpaired t‐test; error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 2 MB enhanced activation and effector function of CTL AEffect of MB on the proliferation of WT CTLs and PD‐1KO CTLs. Splenic cells were stained with 5 μM of CFSE and seeded into aCD3/aCD28‐coated 96‐well plates. 10 μg/ml of PD‐L1 was administered in media. Cell proliferation was checked by monitoring dilution of CFSE 48 h after CD3/CD28 stimulation by gating on CD8‐positive population through FACS analysis. WT: splenic cell from wild‐type C57BL/J mice. PD‐1KO: splenic cell from PD‐1 knockout mice.BStatistical results of (A).CFACS analysis of the effect of MB on the activation of OT‐I CTLs. OT‐I CTLs were stimulated with precoated aCD3/aCD28 and 10 μg/ml of mouse PD‐L1 protein in the presence of 100 nM MB or 10 μg/ml aPD1 (served as positive control). After 24 h, surface expression of CD25 and CD69 on OT‐1 CTLs was determined through FACS analysis.DStatistical results of (C).EEffect of MB on the activation status of Jurkat T cells. Luciferase activity is suppressed in JP‐luc by co‐culture with Raji‐L1 preloaded with 1 μg/ml superantigen (SEE). Treatment with MB enhanced luciferase expression (SEE‐loaded Raji (PD‐L1 negative) served as positive control). IC50 is calculated to be 117 nM. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.FImpact of MB on luciferase activity of various engineered Jurkat T cells. J‐luc: Jurkat cell harboring NFAT‐luciferase transgene; J‐luc‐sgPD‐1: J‐luc cells treated with lentivirus expressing sgPD‐1/CAS9 simultaneously.GqRT–PCR analysis of IL‐2 mRNA level in JP‐luc cells stimulated with precoated aCD3/aCD28 (10 μg/ml) in the presence of 10 μg/ml of PD‐L1 and MB at indicated concentrations.HMB enhancing IL‐2 expression by JP‐luc stimulated with Raji‐L1 for 24 h quantified through ELISA analysis (aPD1 served as positive control).IMB enhancing production of cytokine and cytolytic granule by OT‐I CTLs. CTLs were incubated with EG7‐L1 cells in the presence of protein transport inhibitor (PTI) and MB at indicated concentrations. Expression of cytokine and cytolytic granule was determined by flow cytometry. aPD1 served as positive control. EG7‐L1: EG7 overexpressing PD‐L1.JStatistical results of (I).Data information: Data are representative of three independent experiments. Unpaired t‐test; error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure EV3 MB suppress PD‐1 signaling through blocking SHP2 recruitment by PD‐1 AImpact of MB on the interaction between PD‐1 and PD‐L1. Jurkat‐PD‐1 cells (parental Jurkat cells served as negative control) were incubated with human PD‐L1‐Fc fusion protein in the presence of MB at indicated concentration at 4℃ for 30 min. Cells were stained for PE‐conjugated anti‐hIgG‐Fc antibody. Binding of PD‐L1 on cells was determined by flow cytometry.BLuciferase complementation analysis showing the effect of PD‐1 Y248F mutation on the interaction between PD‐1 and SHP2.CImpact of MB on luciferase activity of various engineered Jurkat T cells. JP‐luc‐sgSHP2: JP‐luc cells treated with lentivirus expressing sgSHP2/CAS9 simultaneously. SHP099: JP‐luc cells treated with 10 μM SHP099. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1.DImpact of MB on cytotoxicity of sgSHP2 or OT‐1 in the presence of 10 μM SHP099 against EG7 or EG7‐L1. EG7‐L1: EG7 overexpressing PD‐L1.ECo‐IP analysis of impact of MB on interaction between SHP2 and EGFR.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; ***P < 0.001.
Figure EV3 MB suppress PD‐1 signaling through blocking SHP2 recruitment by PD‐1 AImpact of MB on the interaction between PD‐1 and PD‐L1. Jurkat‐PD‐1 cells (parental Jurkat cells served as negative control) were incubated with human PD‐L1‐Fc fusion protein in the presence of MB at indicated concentration at 4℃ for 30 min. Cells were stained for PE‐conjugated anti‐hIgG‐Fc antibody. Binding of PD‐L1 on cells was determined by flow cytometry.BLuciferase complementation analysis showing the effect of PD‐1 Y248F mutation on the interaction between PD‐1 and SHP2.CImpact of MB on luciferase activity of various engineered Jurkat T cells. JP‐luc‐sgSHP2: JP‐luc cells treated with lentivirus expressing sgSHP2/CAS9 simultaneously. SHP099: JP‐luc cells treated with 10 μM SHP099. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1.DImpact of MB on cytotoxicity of sgSHP2 or OT‐1 in the presence of 10 μM SHP099 against EG7 or EG7‐L1. EG7‐L1: EG7 overexpressing PD‐L1.ECo‐IP analysis of impact of MB on interaction between SHP2 and EGFR.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; ***P < 0.001.CC BY · PubMed Central
Figure 3 MB suppress PD‐1 signaling through blocking SHP2 recruitment by PD‐1 AConfocal cell images of Jurkat cells co‐expressing PD‐1‐EGFP and SHP2‐mCherry. Jurkat cells co‐expressing PD‐1‐EGFP and SHP2‐mCherry were incubated with 10 μg/ml of human PD‐L1 protein in the presence of 100 nM and 1 μM of MB for 2 min, fixed with 4% paraformaldehyde, and stained with DAPI. Colocalization signal was examined with confocal microscope (scale bar = 2 μm).BFluorescence complementation analysis of the effect of MB on the interaction between PD‐1 and SHP2. Jurkat cells co‐expressing PD1‐C‐Luc or PD1Y248F‐C‐Luc and SHP2‐N‐luc were seeded in a 96‐well plate precoated with 10 μg/ml of aCD3/aCD28 with media supplemented with 10 μg/ml human PD‐L1 protein in the presence of MB at indicated concentrations for 6 h followed by analysis of luciferase activity.CCo‐IP analysis of impact of MB on interaction between PD‐1 and SHP2. 293T cells co‐expressing PD‐1 and SHP2‐FLAG were treated with MB at indicated concentration for 6 h.DAbility of MB to block interaction between PD‐1 with SHP2 revealed through ELISA. Y248‐phosphorylated human PD‐1 ITSM peptide was coated at 4 μg/ml in 96‐well plate overnight. Recombinant human SHP2 protein incubated with the coated peptide in the presence of MB for 2 h. Bound SHP2 was measured by monitoring the activity of horse peroxidase conjugated on secondary antibody targeting SHP2.ERepresentative Western blot showing the levels of total and phosphorylated ZAP70, PKCθ, and PLCγ1 in the lysates of stimulated CTL, inhibited by PD‐L1 in the presence of 1 μM of MB.FRepresentative Western blot showing the levels CD28 phosphorylation. CTL was stimulated with EG7 cells (parental), EG7‐L1, and EG7‐L1 in the presence of 100 nM of MB for 2 h. Protein immunoprecipitated (IP) with anti‐pY from the lysates of the indicated CTL‐EG7 co‐culture was subjected to SDS–PAGE separation and blotted with aCD28. β‐Actin served as loading control. EG7‐L1: EG7 overexpressing PD‐L1.GPhos‐tag analysis of CD28 phosphorylation in CTL. CTLs were stimulated with EG7 or EG7‐L1 in the presence of 1 μM MB. Cell lysate was then separated by SDS–PAGE containing 50 μM of Phos‐tag and blotted with aCD28 antibody. Phosphorylated CD28 (slow‐moving) species were visualized through exposure.HFluorescence complementation analysis of the effect of MB on the interaction between CD28 with P85. Jurkat or Jurkat‐PD‐1 cells were co‐transfected with CD28‐C‐Luc or CD28Y191F‐C‐Luc and P85‐N‐Luc. Cells were seeded in a 96‐well plate coated with 10 μg/ml of aCD3/aCD28 in the presence of human 10 μg/ml of PD‐L1 protein and 100 nM of MB for 6 h. Luciferase activity was measured as readout for CD28‐P85 interaction.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ****P < 0.0001. Source data are available online for this figure.
Figure 3 MB suppress PD‐1 signaling through blocking SHP2 recruitment by PD‐1 AConfocal cell images of Jurkat cells co‐expressing PD‐1‐EGFP and SHP2‐mCherry. Jurkat cells co‐expressing PD‐1‐EGFP and SHP2‐mCherry were incubated with 10 μg/ml of human PD‐L1 protein in the presence of 100 nM and 1 μM of MB for 2 min, fixed with 4% paraformaldehyde, and stained with DAPI. Colocalization signal was examined with confocal microscope (scale bar = 2 μm).BFluorescence complementation analysis of the effect of MB on the interaction between PD‐1 and SHP2. Jurkat cells co‐expressing PD1‐C‐Luc or PD1Y248F‐C‐Luc and SHP2‐N‐luc were seeded in a 96‐well plate precoated with 10 μg/ml of aCD3/aCD28 with media supplemented with 10 μg/ml human PD‐L1 protein in the presence of MB at indicated concentrations for 6 h followed by analysis of luciferase activity.CCo‐IP analysis of impact of MB on interaction between PD‐1 and SHP2. 293T cells co‐expressing PD‐1 and SHP2‐FLAG were treated with MB at indicated concentration for 6 h.DAbility of MB to block interaction between PD‐1 with SHP2 revealed through ELISA. Y248‐phosphorylated human PD‐1 ITSM peptide was coated at 4 μg/ml in 96‐well plate overnight. Recombinant human SHP2 protein incubated with the coated peptide in the presence of MB for 2 h. Bound SHP2 was measured by monitoring the activity of horse peroxidase conjugated on secondary antibody targeting SHP2.ERepresentative Western blot showing the levels of total and phosphorylated ZAP70, PKCθ, and PLCγ1 in the lysates of stimulated CTL, inhibited by PD‐L1 in the presence of 1 μM of MB.FRepresentative Western blot showing the levels CD28 phosphorylation. CTL was stimulated with EG7 cells (parental), EG7‐L1, and EG7‐L1 in the presence of 100 nM of MB for 2 h. Protein immunoprecipitated (IP) with anti‐pY from the lysates of the indicated CTL‐EG7 co‐culture was subjected to SDS–PAGE separation and blotted with aCD28. β‐Actin served as loading control. EG7‐L1: EG7 overexpressing PD‐L1.GPhos‐tag analysis of CD28 phosphorylation in CTL. CTLs were stimulated with EG7 or EG7‐L1 in the presence of 1 μM MB. Cell lysate was then separated by SDS–PAGE containing 50 μM of Phos‐tag and blotted with aCD28 antibody. Phosphorylated CD28 (slow‐moving) species were visualized through exposure.HFluorescence complementation analysis of the effect of MB on the interaction between CD28 with P85. Jurkat or Jurkat‐PD‐1 cells were co‐transfected with CD28‐C‐Luc or CD28Y191F‐C‐Luc and P85‐N‐Luc. Cells were seeded in a 96‐well plate coated with 10 μg/ml of aCD3/aCD28 in the presence of human 10 μg/ml of PD‐L1 protein and 100 nM of MB for 6 h. Luciferase activity was measured as readout for CD28‐P85 interaction.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ****P < 0.0001. Source data are available online for this figure.CC BY · PubMed Central
Figure 4 MB shrinks tumor in vivo through enhancing cytotoxic function of CTL ASchematic of the xenograft mouse model for MB treatment. C57BL/6J mice were inoculated with EG7‐L1 cells (2 × 106 cells, s.c.) on the right flank on day 1, followed by injection (2 × 106 cells, i.v.) of CD45.1+ CTL on day 3 and 6, respectively. The mice were randomized into three groups (n = 5) and treated with vehicle, MB (20 mg/kg/day, i.g.), and aPD1 (10 mg/kg, every other day, i.p.) served as positive control. Tumor size was measured through calipering every other day. EG7‐L1: EG7 overexpressing PD‐L1.BTumor growth curve for (A) was shown as mean ± SEM.CRepresentative image of the tumor on day 10 mentioned in (A).DTumor weight on day 10 (n = 5) mentioned in (A).EImmunohistochemical analysis of cell proliferation marker ki‐67 and CD8 in tumor nodules on day 10 (n = 5) in (A).FStatistical results of (E).GExpression of perforin, GZMB, and IL‐2 by CD8+ CD45.1+ TILs was analyzed by flow cytometry.HStatistical results of (G).ISchematic of EGFR L858R mice treated with MB.JTumor burdens recorded through computed tomography (CT) scanning for EGFR L858R mice (n = 5, lung section = 3). Mice were treated with MB (20 mg/kg/day, i.g.) for 1 week, followed by imaged with CT again to record tumor burden.KStatistical results of (J).LHematoxylin and eosin staining of lung section of EGFR L858R mice (n = 5, lung section = 3) in (J).MStatistical results of (L).Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 4 MB shrinks tumor in vivo through enhancing cytotoxic function of CTL ASchematic of the xenograft mouse model for MB treatment. C57BL/6J mice were inoculated with EG7‐L1 cells (2 × 106 cells, s.c.) on the right flank on day 1, followed by injection (2 × 106 cells, i.v.) of CD45.1+ CTL on day 3 and 6, respectively. The mice were randomized into three groups (n = 5) and treated with vehicle, MB (20 mg/kg/day, i.g.), and aPD1 (10 mg/kg, every other day, i.p.) served as positive control. Tumor size was measured through calipering every other day. EG7‐L1: EG7 overexpressing PD‐L1.BTumor growth curve for (A) was shown as mean ± SEM.CRepresentative image of the tumor on day 10 mentioned in (A).DTumor weight on day 10 (n = 5) mentioned in (A).EImmunohistochemical analysis of cell proliferation marker ki‐67 and CD8 in tumor nodules on day 10 (n = 5) in (A).FStatistical results of (E).GExpression of perforin, GZMB, and IL‐2 by CD8+ CD45.1+ TILs was analyzed by flow cytometry.HStatistical results of (G).ISchematic of EGFR L858R mice treated with MB.JTumor burdens recorded through computed tomography (CT) scanning for EGFR L858R mice (n = 5, lung section = 3). Mice were treated with MB (20 mg/kg/day, i.g.) for 1 week, followed by imaged with CT again to record tumor burden.KStatistical results of (J).LHematoxylin and eosin staining of lung section of EGFR L858R mice (n = 5, lung section = 3) in (J).MStatistical results of (L).Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure EV4 MB shrinks tumor in vivo through enhancing cytotoxic function of CTL AEffect of different concentration of MB on EG7‐L1 xenograft in C57BL/6J mice (n = 5). EG7‐L1: EG7 overexpressing PD‐L1.BEG7‐L1 xenograft growth curve in RAG1−/− mice (n = 2).CEffect of different concentration of MB on xenograft in RAG1−/− mice (n = 2).DTumor growth curves of subcutaneous tumor allograft. EG7‐L1 cell (2 × 106 cells) was subcutaneously injected into the right flank of C57BL/6J mice (n = 4 per group). The mice were then injected with WT or PD‐1KO CTLs (i.v.) on days 3 and 6, respectively, and treated with vehicle, aPD1 (i.p. 10 mg/kg, every other day), or MB (i.g. 20 mg/ kg/day). Tumor volume is shown as mean ± SEM.EExpression of IL‐2, granzyme B, and perforin by CD8+ T Cells was analyzed in tumors of EC mice after treatment with MB by FACS.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure EV4 MB shrinks tumor in vivo through enhancing cytotoxic function of CTL AEffect of different concentration of MB on EG7‐L1 xenograft in C57BL/6J mice (n = 5). EG7‐L1: EG7 overexpressing PD‐L1.BEG7‐L1 xenograft growth curve in RAG1−/− mice (n = 2).CEffect of different concentration of MB on xenograft in RAG1−/− mice (n = 2).DTumor growth curves of subcutaneous tumor allograft. EG7‐L1 cell (2 × 106 cells) was subcutaneously injected into the right flank of C57BL/6J mice (n = 4 per group). The mice were then injected with WT or PD‐1KO CTLs (i.v.) on days 3 and 6, respectively, and treated with vehicle, aPD1 (i.p. 10 mg/kg, every other day), or MB (i.g. 20 mg/ kg/day). Tumor volume is shown as mean ± SEM.EExpression of IL‐2, granzyme B, and perforin by CD8+ T Cells was analyzed in tumors of EC mice after treatment with MB by FACS.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 5 MB is effective to activate human CD8+ T cells AEffect of MB on proliferation of human CD8+ T cells. CFSE‐labeled human peripheral blood mononuclear cells (PBMC) were preincubated with DMSO, MB, 25 μg/ml of pembrolizumab, or 20 μg/ml of nivolumab for 1 h and then seeded in the 96‐well plate precoated with 10 μg/ml of aCD3/aCD28 in the presence of 10 μg/ml human PD‐L1 protein. Cell proliferation was analyzed through FACS analysis of dilution of CFSE.BCytokine and cytolytic granule production in CD8+ T cells. Human peripheral blood mononuclear cells from healthy donators were stimulated with 5 μg/ml of phytohaemagglutinin for 2 days and then rested for 1 day. Cells were pretreated with DMSO, MB, 25 μg/ml of pembrolizumab (Pem), or 20 μg/ml of nivolumab (Niv) for 1 h and then seeded in a 96‐well plate precoated with 10 μg/ml aCD3/aCD28, with media supplemented with 10 μg/ml of human PD‐L1 protein. Cytokine and cytolytic granule production was determined by intracellular flow cytometry by gating on CD8+ populations.CComparison of the efficacy of MB with PD1 inhibitors currently used in clinic to activate T cell. JP‐luc cells were stimulated with Raji‐L1 or parental Raji cells preloaded with 1 μg/ml of superantigen (SEE) in the presence of MB at indicated concentration or 25 μg/ml of pembrolizumab (Pem) or 20 μg/ml of nivolumab (Niv) for 6 h. Luciferase activity was measured by luminometer. Data are representative of three independent experiments and were analyzed by unpaired t‐test. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. **P < 0.01; ****P < 0.0001.
Figure 5 MB is effective to activate human CD8+ T cells AEffect of MB on proliferation of human CD8+ T cells. CFSE‐labeled human peripheral blood mononuclear cells (PBMC) were preincubated with DMSO, MB, 25 μg/ml of pembrolizumab, or 20 μg/ml of nivolumab for 1 h and then seeded in the 96‐well plate precoated with 10 μg/ml of aCD3/aCD28 in the presence of 10 μg/ml human PD‐L1 protein. Cell proliferation was analyzed through FACS analysis of dilution of CFSE.BCytokine and cytolytic granule production in CD8+ T cells. Human peripheral blood mononuclear cells from healthy donators were stimulated with 5 μg/ml of phytohaemagglutinin for 2 days and then rested for 1 day. Cells were pretreated with DMSO, MB, 25 μg/ml of pembrolizumab (Pem), or 20 μg/ml of nivolumab (Niv) for 1 h and then seeded in a 96‐well plate precoated with 10 μg/ml aCD3/aCD28, with media supplemented with 10 μg/ml of human PD‐L1 protein. Cytokine and cytolytic granule production was determined by intracellular flow cytometry by gating on CD8+ populations.CComparison of the efficacy of MB with PD1 inhibitors currently used in clinic to activate T cell. JP‐luc cells were stimulated with Raji‐L1 or parental Raji cells preloaded with 1 μg/ml of superantigen (SEE) in the presence of MB at indicated concentration or 25 μg/ml of pembrolizumab (Pem) or 20 μg/ml of nivolumab (Niv) for 6 h. Luciferase activity was measured by luminometer. Data are representative of three independent experiments and were analyzed by unpaired t‐test. JP‐luc: Jurkat cell harboring NFAT‐luciferase transgene and overexpressing PD‐1; Raji‐L1: Raji overexpressing PD‐L1.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. **P < 0.01; ****P < 0.0001.CC BY · PubMed Central
Figure EV5 MB is effective to activate human CD8+ T cells ABar graph of proliferation of human CD8 T cells.BBar graph of IL‐2 production of human CD8+ T cells.CBar graph of IFNγ production of human CD8+ T cells.DBar graph of perforin production of human CD8+ T cells.EBar graph of GZMB production of human CD8+ T cells.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure EV5 MB is effective to activate human CD8+ T cells ABar graph of proliferation of human CD8 T cells.BBar graph of IL‐2 production of human CD8+ T cells.CBar graph of IFNγ production of human CD8+ T cells.DBar graph of perforin production of human CD8+ T cells.EBar graph of GZMB production of human CD8+ T cells.Data information: Data are representative of three independent experiments and were analyzed by unpaired t‐test. Error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 63

Metadata

Authors
Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L.
Affiliations
  • Jinan University (CN)
  • Sun Yat-sen University Cancer Center (CN)
  • University of East Anglia (GB)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Zhou, Penghui
  • Ding, Ke
  • Chen, Liang
Venue
EMBO Molecular Medicine
Published
2020-05-11
Volume
12
Issue
6
Pages
e11571-e11571
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3023016632
Cited by
62
References
51
Citations by year
2026: 7 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 17 · 2021: 6 · 2020: 3
FWCI
3.07
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81672309, 81972778, 31800723, 31701174)
  • Guangzhou Research Project of Science and Technology for Citizen Health (201803010124)
  • Science and Technology Program of Guangdong (2017B020227001)
  • Fundamental Research Funds for the Central Universities (21618326)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-1, SHP2, methylene blue, PD-1/PD-L1 axis, CD8+ cytotoxic T lymphocytes, lung cancer, immunotherapy, tumor allografts
MeSH terms
Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors. https://app.cochat.ai/papers/10.15252/emmm.201911571
The paper
Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L. (2020). Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201911571

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.